Abstract: Novel diaminothiazoles of formula (I): are discussed. These compounds selectively inhibit the activity of Cdk4 and are thus useful in the treatment or control of cancer, in particular, the treatment or control of solid tumors. This invention also provides pharmaceutical compositions containing such compounds and methods of treating or controlling cancer, most particularly, the treatment or control of breast, lung, colon, and prostate tumors.

Abstract: A phenylpyridazine derivative represented by the formula (1): Wherein, R1, R2, R3, X, Y, Z and n have the same meaning as defined in the specification; or a salt thereof, or a medicine containing the compound. The present invention provides water-soluble phenylpyridazine derivatives and medicines containing them, which have excellent inhibitory activity against interleukin-? production, high water solubility and high oral absorbability.

Abstract: This invention relates to nitrogenous (tetrahydropyridyl)(alkyl)heterocycles, to pharmaceutical compositions comprising them, to processes for preparing them and to the method of use thereof in the treatment of pain and diseases related to immune and inflammatory disorders.

Abstract: The present invention relates to compounds of formula I wherein R is methyl; and R1 is 4-methyl-4-oxy-piperazin-1-yl; or R is CH2OH and R1 is 4-methyl-piperazin-1-yl or is 4-methyl-4-oxy-piperazin-1-yl; and to pharmaceutically acceptable acid addition salts thereof for the treatment of NK-1 receptor related diseases, for example depression, Parkinson's disease, Alzheimer's disease, anxiety, emesis, and pain.

Abstract: Compounds, compositions and methods useful for treating cellular proliferative diseases and disorders, for example, by modulating the activity of KSP, are disclosed.

Abstract: The invention relates to a 2-(diaza-bicyclo-alkyl)-pyrimidone derivative represented by formula (I): wherein: R1 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; R2 represents a hydrogen atom, a C1-6 alkyl group optionally substituted by 1 to 4 substituents selected from a halogen atom, a hydroxyl group, a C1-4 alkoxy group; a C1-2 perhalogenated alkyl group, a benzyl group, a phenethyl group, a benzyloxycarbonyl group, a C1-4 alkoxy carbonyl group, a benzene ring, a naphthalene ring, a quinoline ring, a phthalazine ring, a 5,6,7,8-tetrahydronaphthalene ring, a pyridine ring, an indole ring, a pyrrole ring, a thiophene ring, a benzenesulfonyl group, a benzoyl group, a pyridazine ring, a furan ring and an imidazole ring; each of the benzyl group, the phenethyl group, the benzyloxycarbonyl group, the benzenesulfonyl group, the benzoyl group and the benzene, naphthalene, quinoline, phthalazine, 5,6,7,8-tetrehydronaphthalene, pyridine, indole, pyrrole and thiophene rings being optionally sub

Abstract: Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.

Abstract: The invention relates to substituted 7-azaindoles, process for their preparation, pharmaceutical preparations which comprise these compounds, and the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active ingredients for the treatment of disorders which can be influenced by inhibition of phosphodiesterase 4 activity in particular in immunocompetent cells (e.g. macrophages and lymphocytes) by the compounds of the invention.

Abstract: The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some tetrahydroisoquinoline propyl sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is involved, such as CNS disorders.

Abstract: The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some tetrahydroisoquinoline substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is involved, such as CNS disorders.

Abstract: The invention is directed to physiologically active compounds of formula (I): wherein: R1 represents optionally substituted aryl, optionally substituted heteroaryl, R3NH—Ar1—L2— or R3—NH—C(?O)—NH—Ar2—L2—; R3 represents aryl or heteroaryl; Ar1 represents a saturated, partially saturated or fully unsaturated 8- to 10-membered bicyclic ring system containing at least one heteroatom selected from O, S or N; Ar2 represents aryldiyl or heteroaryldiyl; L1 represents a linkage, such as an alkylene linkage; L2 represents an alkylene chain linkage; R2 represents hydrogen, halogen, C1-4alkyl or C1-4alkoxy; and Y is carboxy or an acid bioisostere; but excluding compounds where an oxygen, nitrogen or sulfur atom is attached directly to a carbon carbon multiple bond of an alkenylene or alkynylene residue; and the corresponding N-oxides and ester prodrugs thereof, and the pharmaceutically acceptable salts and solvates of such compounds, and the N-oxides and ester prodrugs thereof.

Abstract: An object of the present invention is to provide compounds having potent antitumor activity. The compounds according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: wherein X and Z represent CH or N; Y represents O or S; R1, R2, and R3 represent H, alkoxy or the like; R4 represents H; R5, R6, R7, and R8 represent H, halogen, alkoxy or the like; R9 and R10 represent H, alkyl or the like; and R11 represents optionally substituted azolyl.

Abstract: The invention relates to novel N-substituted indolyl-3-glyoxylamides of the general formula I, their preparation and use as medicaments, in particular for the treatment of tumors

Abstract: The present invention provides a novel compound exhibiting an excellent suppressing effect to cell injury caused by radicals and neurotoxicity induced by excitatory nuerotransmitters such as glutamate. Specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein Z represents a bivalent organic group and the like of from 2 to 3 carbon atom(s) which may have a substituent; and R3 represents a carboxyl group and the like.

Abstract: The invention describes novel nitrosated proton pump inhibitor compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated proton pump inhibitor compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated proton pump inhibitor compound, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent.

Abstract: A peroxisome proliferator activated receptor regulator containing a carboxylic acid derivative of formula (I) (wherein all symbols are as defined in the specification), a non-toxic acid thereof or a hydrate thereof as active ingredient. Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and/or a remedy for diseases associating metabolic disorders (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipemia, atherosclerosis, hypertension, circulatory diseases, overeating, coronary heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and/or VLDL cholesterol-lowering agent and a drug for relief from risk factors of diseases or syndrome X.

Abstract: The invention relates to substituted and unsubstituted 3H-benzo[1,2,3]oxathiazole 2,2-dioxides, 1,3-dihydrobenzo[1,2,5]thiadiazole 2,2-dioxides and 1,3-dihydro-benzo[c]isothiazole 2,2-dioxides, to their preparation and to their use in medicaments.

Abstract: The present invention relates to compounds useful in the treatment of cancer or other proliferative diseases represented by the formula wherein: R1, R2, R3, R4, R5 are hydrogen or lower alkyl; R6 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, or heterocyclo; X is hydrogen and Y is hydroxy, or X and Y taken together represent a carbon-carbon bond; and pharmaceutically acceptable salts, solvates, or hydrates thereof. Also included are therapeutic compositions containing the compounds represented by formula I as active ingredients, alone or in combination with other therapeutic agents useful in the treatment of cancer or other proliferative diseases.

Abstract: This invention is generally directed to Indazole Derivatives having the following structure: or pharmaceutically acceptable salt thereof, wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhibition, such as an inflammatory disease or disorder. Thus, methods of treating such diseases and disorders are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

Abstract: Substituted imidazoles and thiazoles having the formula are useful for inhibiting farnesyltransferase. Also disclosed are farnesyltransferase-inhibiting compositions and methods of inhibiting farnesyltransferase in a patient.

Abstract: An injection which contains as the active ingredient a pyrazolone derivative which typically is Edaravone, a physiologically acceptable salt thereof, or a hydrate or solvate of either in an amount of 3 to 60 mg/mL. It is excellent in long-term stability, product storage, and suitability for use.

Abstract: The present invention relates to compounds of Formula I: wherein A is (CH2)m-Q-(CH2)n, wherein each CH2 may be independently substituted with one or more substitution selected from the group consisting of: hydroxy, halo, alkoxy, lower alkyl, amino, aminoalkyl, alkylamino, alkenyl, and alkynyl; B is a 5 or 6 membered heteroaryl, or aryl, optionally saturated, or optionally substituted with R1, R2, or R12; X is selected from the group consisting of: N and C; and Y and Z are independently selected from the group consisting of: N, C, CH, CR3, S, and O; compositions comprising such compounds, intermediates thereof, methods of making such compounds, and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis.

Abstract: The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors having at least one oxime group or hydrazone group and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor having at least one oxime group or hydrazone group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor having at least one oxime group or hydrazone group, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention having at least one oxime group or hydrazone group can be optionally nitrosated and/or nitrosylated.

Abstract: The present invention provides a therapeutic method to treat non-malignant diseases characterized by the excessive tissue growth, e.g., hyperplastic diseases, comprising administering to a mammal (e.g.

Abstract: The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity c-kit kinase.

Abstract: The present invention is related to pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin, including premature labor, premature birth and dysmenorrhea.

Abstract: The present invention provides methods and compositions for modulating polyamine pathway activity as a means for ameliorating neurodegenarative disorders. In particular, for ameliorating the symptoms or onset of amyotrophic lateral sclerosis (ALS) by modulating the gene and protein products involved the polyamine pathway, such as by inhibiting the enzyme, ornithine decarboxylase (ODC), involved in the synthesis of the polyamine, putrescine. Compositions and methods are disclosed for inhibiting the polyamine pathway producing lower polyamine levels resulting in a beneficial effect on ALS. This can be accomplished by using modulating agents such as analogs, or polyamine analogs, and antiproliferative drugs. Screening assays for pharmacological agents that are capable of decreasing polyamine levels and/or reducing cell proliferation are also disclosed.

Abstract: The invention provides novel tetradentate enediyne ligands that are themselves thermally stable, yet react at about room temperature or slightly higher upon addition of metal ions or under photothermal conditions. In another aspect of the invention, a method of treating a disorder in a mammal comprising administering a therapeutically effective amount of a compound or composition is provided. In addition, the free ligand can be delivered to the mammal prior to complexation to metals, such that the ligand is exposed to a metal in the body and forms a metal complex in vivo. Furthermore, a metal complex of the invention can be administered to the mammal such that the complex exchanges the first metal center with another endogenous metal in order to form a second metal complex in vivo. The second metal complex is capable of forming a benzenoid diradical under physiological conditions and/or under photothermal conditions.

Abstract: Compounds used to block non-essential androgen receptors are described. In particular, cyclohexenone compounds containing an alkyl group may be used in the treatment of conditions mediated by the blocking of non-essential androgen receptors such as acne, male patterned baldness, keloids, skin-wrinkling, and osteoarthritis. The cyclohexenone compound may be administered orally, topically, or internally.

Abstract: An aerogel material with surfaces containing fluorine atoms which exhibits exceptional hydrophobicity, or the ability to repel liquid water. Hydrophobic aerogels are efficient absorbers of solvents from water. Solvents miscible with water are separated from it because the solvents are more volatile than water and they enter the porous aerogel as a vapor across the liquid water/solid interface. Solvents that are immisicble with water are separated from it by selectively wetting the aerogel. The hydrophobic property is achieved by formulating the aerogel using fluorine containing molecules either directly by addition in the sol-gel process, or by treating a standard dried aerogel using the vapor of fluorine containing molecules.

Abstract: Disclosed herein is a process for the preparation of dimethylether from hydrocarbons, including tri-reforming a feedstock mixture comprised of hydrocarbons, carbon dioxide and water vapor in the presence of a tri-reforming catalyst, to prepare a syngas, which then undergoes gas-phase direct synthesis into dimethylether in one step in the presence of a hybrid catalyst. According to the process of this invention, three main processes among typical syngas preparation processes are simultaneously performed, and then, the syngas thus obtained is prepared into dimethylether through a direct reaction in one step, thereby decreasing the apparatus cost and operation cost. In addition, all of the carbon dioxide separated and recovered from the unreacted material and by-products may be reused as reaction material, thus decreasing the generation of carbon dioxide and reducing the material cost.

Abstract: Nanostructured chromium(III)-oxide-based materials using sol-gel processing and a synthetic route for producing such materials are disclosed herein. Monolithic aerogels and xerogels having surface areas between 150 m2/g and 520 m2/g have been produced. The synthetic method employs the use of stable and inexpensive hydrated-chromium(III) inorganic salts and common solvents such as water, ethanol, methanol, 1-propanol, t-butanol, 2-ethoxy ethanol, and ethylene glycol, DMSO, and dimethyl formamide. The synthesis involves the dissolution of the metal salt in a solvent followed by an addition of a proton scavenger, such as an epoxide, which induces gel formation in a timely manner. Both critical point (supercritical extraction) and atmospheric (low temperature evaporation) drying may be employed to produce monolithic aerogels and xerogels, respectively.

Abstract: A modified filler used in the making of paper or the like, preparation of the filler and its use. The modified filler comprises a filler known as such, e.g. Calcium carbonate, kaolin, talc, titanium dioxide, sodium silicate and aluminum trihydrate or their mixture, and a hydrophobic polymer made of polymerisable monomers, which is added to the filler as a polymer dispersion or a polymer solution.

Abstract: The invention provides a composition comprising particles of an optionally halogenated phthalocynine (a); from 0.5 to 10% weight, preferably from 2 to 8% by weight, based on the optionally halogenated phthalocyanine (a), or a vinylic or acrylic polymer (b); and from 1 to 15% by weight, preferably from 3 to 10% by weight, based on the optionally halogenated phthalocyanine (a), of an optionally halogenated phthalocyanine (c) which is outside the particles of the optionally halogenated phthalocyanine (a) and is substituted by a group comprising at least 1 hetero atom selected from the group consisting of N, O, S and P and at least 3 carbon atoms. The instant compositions comprising three essential components are surprisingly warpfree in substrate such as partially crystalline plastics, especially those processed by injection moulding. Geometrically identical parts of different colours are obtained.

Abstract: A golf ball material comprises a heated mixture having a melt index of at least 1.0 dg/min, which mixture is composed of (A) a thermoplastic resin, (B) a fatty acid or fatty acid derivative having a molecular weight of at least 280, and (C) a basic inorganic metal compound capable of neutralizing acidic groups in components A and B. The material including a highly neutralized ionomer resin has good thermal stability, flow characteristics and moldability. The invention is also directed at high-rebound golf balls which can be easily and efficiently manufactured using the same material.

Abstract: Non-petroleum based oils replace traditional process oils used in rubber compositions in general and specifically in footwear applications. The replacement oils, derived from plant or animal sources, represent a renewable resource and provide other advantages. The oils contain a sufficient level and distribution of fatty acid side chains to partially incorporate into the rubber at low levels, and to act as internal plasticizers at higher levels. Other compositions are free of silane coupling agents and additives that generate carcinogenic nitrosamines.

Abstract: A tread rubber composition improved both in grip performance on ice-covered and snow-covered road surfaces and in abrasion resistance is provided. The tread rubber composition contains aluminum hydroxide having an untamped density of not more than 0.60 g/cm3, a DOP oil absorption of at least 70 cm3/100 g and less than 250 cm3/100 g, and a BET specific surface area of at least 30 m2/g and not more than 350 m2/g in an amount of 5–60 parts by weight with respect to 100 parts by weight of a rubber component containing at least 50% by weight of at least one of polyisoprene rubber and polybutadiene rubber. The tread rubber composition has a tan? peak temperature of not more than ?45° C. and a type A durometer hardness at 0° C. of not more than 64.

Abstract: The present invention is directed, in part, to improved nanocomposite compositions and processes for preparing same. Specifically, in one embodiment, there is provided a process for preparing an aqueous nanocomposite dispersion, wherein the process comprises: polymerizing via suspension polymerization a suspension comprising at least one ethylenically unsaturated monomer and a hydrophobically modified clay to form the nanocomposite dispersion after polymerization, wherein the hydrophobically modified clay is dispersed in the monomer. Other embodiments include processes for preparing aqueous nanocomposite particles, colloids, and dispersions using hydrophobically modified clays in aqueous systems and compositions comprising same.

Abstract: The invention concerns an insulating nozzle for a gas blast circuit breaker. In accordance with the invention, the material constituting the nozzle comprises (A) 90% to 99.9% by weight of a fluorinated polymer, and (B) 0.1% to 10% by weight of a filler based on at least one oxide selected from (B1) SiO2 and other oxidized forms of metals from column IVA of the periodic table, and (B2) ZnO, CdO and other oxidized forms of metals from column IIB of the periodic table.

Abstract: A composition containing from 88 to 99.99% by weight of a polyamide, a compound of a polyamide and mixtures of these, and from 0.01 to 0.25% by weight of a flow aid where the drying loss from the flow aid after 5 days of conditioning at a relative humidity of 95% is less than or equal to 1%, determined by ISO 787/2.

Abstract: The present invention relates to an adhesive and more particularly to a moisture curable adhesive. In one embodiment, the present invention includes a moisture curable adhesive comprising a polymer or copolymer including reactive silicon end groups; from about 0.01 to about 40 percent by weight of a clear filler that will not substantially interfere with the clarity of the adhesive; and from about 0.01 to about 10 percent by weight of a dehydrating agent. In another embodiment, the present invention includes a moisture curable adhesive comprising a copolymer including a reactive silicon group; from about 33 to about 85 percent by weight of a filler; and from about 0.01 to about 10 percent by weight of a dehydrating agent. The present invention is further directed to a method of joining two adherends.

Abstract: Waste toner is fused and kneaded with modified polyphenylene ether so as to be used as a molding material. The waste toner preferably includes a toner ingredient including styrene-acrylic resins. With this arrangement, it is possible to inexpensively manufacture a molding product which has excellent physical properties such as tensile strength, flexural rigidity, and flexural strength and is usable for various purposes.

Abstract: An object of the present invention is to provide a paint composition for in-mold coating of thermoplastic plastic substrates, the paint film resultant from which composition neither peels off nor becomes turbid even if the mold is opened in a state where its temperature is high, needless to say that the resultant paint film has excellent adhesion to nonpolar thermoplastic plastic substrates and adequate flowability. As a means of achieving this object, a paint composition according to the present invention for in-mold coating of thermoplastic plastic substrates comprises: an acryl-modified unsaturated dicarboxylic acid (anhydride)-grafted polyolefin (A); at least one member (B) selected from the group consisting of reactive oligomers and reactive monomers; and a radical polymerization initiator (C); in a specific formulation ratio, with the paint composition being characterized in that: the acryl-modified unsaturated dicarboxylic acid (anhydride)-grafted polyolefin (A) is in the range of 92 to 112° C.

Abstract: A stabilized high-vinyl polybutadiene composition comprising a high-vinyl polybutadiene, and an antioxidant defined by the formula where each R1 and R2, which may be the same or different, are mono-valent organic groups, or where each R1, which may be the same or different, is a mono-valent organic group and the two R2 groups join to form a divalent organic group.

Abstract: The present invention relates to foldable polyolefin film compositions, comprising a blend of high density polyethylene, linear low density polyethylene, a magnesium silicate and an alkaline or alkaline earth metal carbonate, to foldable polyolefin films made from such compositions and to a method for producing such.

Abstract: Polyurethaneurea resins containing at least one group of the formula (I) —NH(CO)XOR1O(CO)CHR2CH2N[CnH2nSi(OR3)3](CO)NH—??(I) and/or at least one group of the formula (II) {—NH(CO)XO}a{CH2?CR2(CO)O}bR4{O(CO)CHR2CH2N[CnH2nSi(OR3)3](CO)NH—}c??(II) wherein X=[O(CH2)4]q(OC2H4)x(OC3H6)y[(CH2)5(CO)]z; q=0 to 10; x=0 to 20; y=0 to 20; z=0 to 10; n=2 or 3; a=1 or 2; b=0 to 4; c=1 to 5; R1=—C2H4—, —C3H6—, —C4H8—, —CH(CH2O(CO)R5)CH2— or —CH2CH(O(CO)R5)CH2—; R2=H or CH3; R3=C1 to C4 alkyl; R4=a+b+c-valent, saturated hydrocarbon residue of a (cyclo)alkane polyol with a+b+c hydroxyl groups; R5=an acid residue of a monocarboxylic acid, with the proviso that a+b+c=3 to 6 and wherein the sequence of the subformulae indicated q, x, y and z may be varied at will and q, x, y and z in each case merely state the number of instances of the particular subformulae contained in the formulae (I) and (II).

Abstract: An object of the present invention is to provide an aqueous resin composition and its uses, wherein the aqueous resin composition combines the blocking resistance and the frost damage resistance and thereby can secure the durability over a long period of time even under circumstances where a severe temperature cycle is present. As a means of achieving this object, the aqueous resin composition according to the present invention is an aqueous resin composition comprising an acrylic resin emulsion and a crosslinking agent as essential components, with the aqueous resin composition being characterized in that, when a coating film is formed from the aqueous resin composition, the formed coating film exhibits an elongation ratio (E (%)) that satisfies a specific relational expression along with the glass transition temperature (TgT (° C.)) of the acrylic resin in the emulsion.

Abstract: A method of producing a synthetic polymer blend comprising steps of (i) blending a styrene-butadiene-styrene thermoplastic elastomer (SBS) with a compatibilizer selected from the group consisting of polybutadiene grafted polystyrene resin (HIPS), styrene-hydrogenated-butadiene-styrene (SEBS) and poly-dimethyl-phenylene-oxide (PPO), and dispersing particles of said SBS to a mean particle size of substantially 3 microns or less in diameter, to form an intermediary ingredient, wherein weight ? ? of ? ? the ? ? SBS weight ? ? of ? ? the ? ? compatibilizer is substantially 1 4 to 4; and (ii) blending the intermediary ingredient in the step b) with further ingredient(s) including at least general purpose polystyrene (GPPS), and further dispersing the SBS particles, to form the synthetic polymer blend, wherein weight ? ? of ? ? the ? ? intermediary ? ? ingredient weight ? ? of ? ? the ? ? GPPS is substantially 1 19 ? ? to ? ? 5 6

Abstract: Golf equipment having improved cut and shear resistance that includes a polyurea-based composition or polyurethane-based composition, preferably saturated and/or water resistant, formed of a prepolymer, a functionalized block copolymer, and optionally further cured or chain extended with a curing agent, where the prepolymer is incorporated at the terminal end of the functionalized block copolymer.

Abstract: Provided are a thermoplastic resin composition which is excellent in oil resistance, heat resistance, weatherability, impact resistance, transparency, and moldability, and which can be produced economically, an elastomer composition with low hardness and high tensile strength which is excellent in oil resistance and compression set, and a molded object produced by molding the thermoplastic resin composition or elastomer composition. The composition is produced by compounding a thermoplastic resin or an elastomer with a block copolymer having at least one methacrylic ester polymer block and at least one acrylic ester polymer block.